Molecular Pharmacology Program
The David Scheinberg Lab
Research
The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (Blood, 2010), and a vaccine to WT1 in Phase III trials. Read full article in Science.
We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013), and cellular micropharmacies (Nature Chem.Biol., 2021).
Research Projects
Featured News
People
David A. Scheinberg, MD, PhD
Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery
- Molecular Pharmacology Program Member David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
- MD, PhD, Johns Hopkins University School of Medicine
- scheinbd@mskcc.org
- Email Address
- 646-888-2190
- Office Phone
- View physician profile
- Physician profile
Members
- Molecular Pharmacology Program
- Department of Medicine
- Center for Experimental Therapeutics
- Center for Cell Engineering
- Geoffrey Beene Cancer Research Center
- Center for Molecular Imaging & Bioengineering
- Tri-Institutional PhD Program in Chemical Biology
- Gerstner Sloan Kettering Graduate School of Biomedical Sciences
